Targeting

CZ BioMed products; novel oncolytic viruses, have been genetically engineered to selectively target tumor cells, but not normal cells.
Attacking

Targeted virus replication in tumor cells generates thousands of new therapeutic copies, resulting in the oncolysis of cancer cells and release of the new therapeutic copies to target the adjacent cancer cells in the tumor mass. Therapeutic copies also spread within the body to target and attack distant tumor sites.
Eradicating

The primary replication of oncolytic viruses directly kill the targeted tumor cells, and the explosion cancer cell activates a cascade of anti-tumor immune response.
Induce interferon simultaneously, these payloads act in concert with the primary oncolysis mechanism to eradicate cancer.
Action of RVLYSIS
An oncolytic virus
Selectively kills cancer cells, not normal cells
Selectively Induces apoptosis in tumor cells
Allows interferon (IFN) to achieve high local concentration upon local administration
Local IFN limits viral replication in normal cells around
Induces systemic immunoresponses to indirectly antitumor